Daewon Pharm (003220)

Currency in KRW
13,050
-50(-0.38%)
Closed·

003220 Financial Summary

Key Ratios

P/E Ratio24.77
Price/Book1.04
Debt / Equity65.01%
Return on Equity2.13%
Dividend Yield2.30%
EBITDA46.77B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of KRW (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 536.93%
Dividend Yield
2.30%
Industry Median 0.93%
Annualised payout
300.00
Paid annually
5-Years Growth
+5.15%
Growth Streak

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 19,000
(+45.59% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
251.00 / --
Revenue / Forecast
157.80B / 133.50B
EPS Revisions
Last 90 days

FAQ

What were Daewon Pharm's earnings for the latest quarter?

The Daewon Pharm EPS (TTM) is 536.93. Daewon Pharm reported sales of 157,831.74, net income of 5,422.29, and EPS of 251.00 for the latest quarter.

What was Daewon Pharm's net income for the latest quarter?

Daewon Pharm's net income for the latest quarter was 5,422.29.

What is Daewon Pharm's net profit margin on a TTM basis?

Daewon Pharm's trailing twelve months (TTM) net profit margin is 2.38%.

How does Daewon Pharm's debt to equity ratio compare to industry standards?

Daewon Pharm's total debt-to-equity ratio is 65.01%.

What is Daewon Pharm's return on investment on a TTM basis?

Daewon Pharm's trailing twelve months (TTM) return on investment (ROI) is 2.13%.

Did Daewon Pharm gain or lose cash last quarter?

In the latest quarter, Daewon Pharm's net change in cash was -2,456.07 million.

What were Daewon Pharm's total assets and liabilities in the latest quarter?

As of the latest quarter, Daewon Pharm reported total assets of 598,650.80 million and total liabilities of 219,321.20 million.

What is Daewon Pharm's gross margin on a TTM basis?

Daewon Pharm's trailing twelve months (TTM) gross margin is 46.80%.

What was Daewon Pharm's revenue per share for the latest quarter?

Daewon Pharm's revenue per share for the latest quarter was 14,478.79.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.